IMPACT OF ATORVASTATIN ON CEREBRAL PERFUSION AND ENDOTHELIAL FUNCTION

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本研究的受试者招募已完成。 高血胆固醇是阿尔茨海默病（AD）的危险因素，并导致血管功能受损和脑血流量减少-AD发展的早期发现。他汀类降胆固醇药物可以改善血管功能，增加动物大脑的血流量。目前还不清楚他汀类药物是否会增加人类大脑中的血流量，或者在AD症状出现之前改善大脑中的磁共振成像（MRI）思维激活模式。 本研究的目的是确定阿托伐他汀治疗对脑血流量和思维激活模式的影响，通过MRI测量AD患者的无症状成年儿童。 16个健康的，中年成人儿童的人与AD已被招募为这个为期4个月的试验。 在基线、1个月和4个月访视时，收集受试者的空腹血液检查（AST、ALT、CK、Cr、血脂），并审查副作用或健康变化。在基线和4个月时，收集脑部MRI和血管超声测量结果。受试者随机接受阿托伐他汀40 mg每晚（n=8）与安慰剂（n=8）。 所有受试者将于2007年4月完成研究程序。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Subject recruitment for this study is complete. High blood cholesterol is a risk factor for Alzheimer's disease (AD) and contributes to impaired blood vessel function and decreased brain blood flow - early findings in the development of AD. Cholesterol-lowering medications called statins improve blood vessel function and increase blood flow to the brain in animals. It is unknown whether statins will increase blood flow in the human brain or will improve magnetic resonance imaging (MRI) thinking activation patterns in the brain before symptoms of AD develop. The objective of this study is to determine the effects of atorvastatin therapy on brain blood flow and thinking activation patterns as measured by MRI in asymptomatic adult children of persons with AD. Sixteen healthy, middle-aged adult children of persons with AD have been recruited for this 4-month trial. At baseline, 1-month, and 4-month visits, subjects had fasting blood tests collected (AST, ALT, CK, Cr, lipid profile) and reviewed side effects or changes in their health. At baseline and 4 months, brain MRI and blood vessel ultrasound measures were collected. Subjects were randomized to receive atorvastatin 40 mg nightly (n=8) vs. placebo (n=8). All subjects will have completed study procedures in April 2007.